SABR-BRIDGE:
COVID-19
SABR lung
SBRT (stereotactic body radiation therapy)
lobectomy (lung)
lung cancer
nonsmall cell lung cancer
pulmonary metastases
sublobar pulmonary resection
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
07
2020
accepted:
20
08
2020
entrez:
19
10
2020
pubmed:
20
10
2020
medline:
20
10
2020
Statut:
epublish
Résumé
Surgical resection is the standard-of-care approach for early-stage non-small cell lung cancer (NSCLC). Surgery is also considered an acceptable standard infit patients with oligometastatic lesions in the lungs. The COVID-19 pandemic has led to worldwide issues with access to operating room time, with patients and physicians facing uncertainty as to when surgical resection will be available, with likely delays of months. Further compounding this are concerns about increased risks of respiratory complications with lung cancer surgery during active phases of the pandemic. In this setting, many thoracic oncology teams are embracing a paradigm where stereotactic ablative radiotherapy (SABR) is used as a bridge, to provide radical-intent treatment based on a combination of immediate SABR followed by planned surgery in 3-6 months. This pragmatic approach to treatment has been named SABR-BRIDGE (Stereotactic ABlative Radiotherapy Before Resection to avoId Delay for early-stage lunG cancer or oligomEts). This term has also been applied to the pragmatic study of the outcomes of this approach. In this paper, we discuss the standards of care in treatment of early-stage (NSCLC) and pulmonary oligometastases, the impetus for the SABR-BRIDGE approach, and the controversies surrounding assessment of pathological response to neo-adjuvant radiation therapy.
Identifiants
pubmed: 33072612
doi: 10.3389/fonc.2020.580189
pmc: PMC7544973
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
580189Informations de copyright
Copyright © 2020 Kidane, Spicer, Kim, Fiset, Abdulkarim, Malthaner and Palma.
Références
J Thorac Dis. 2019 Apr;11(Suppl 7):S969-S975
pubmed: 31183179
Lancet Oncol. 2015 Jun;16(6):630-7
pubmed: 25981812
Br J Radiol. 2016 Sep;89(1065):20160113
pubmed: 27245137
Ann Thorac Surg. 2017 Apr;103(4):1070-1075
pubmed: 28110809
Nat Rev Clin Oncol. 2010 Jan;7(1):44-54
pubmed: 19997074
Lancet Respir Med. 2018 Dec;6(12):915-924
pubmed: 30442588
Oncology. 2007;73(5-6):316-23
pubmed: 18497503
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Oncotarget. 2017 Nov 28;9(2):1630-1640
pubmed: 29416719
J Thorac Oncol. 2020 May;15(5):709-740
pubmed: 32004713
J Clin Oncol. 2019 Jun 20;37(18):1558-1565
pubmed: 31067138
BMC Cancer. 2019 Jun 28;19(1):639
pubmed: 31253136
J Thorac Cardiovasc Surg. 2019 Oct;158(4):1234-1241.e16
pubmed: 31395367
Curr Surg Rep. 2016;4(11):37
pubmed: 27730011
World J Surg. 2016 Dec;40(12):2976-2983
pubmed: 27456499
Pract Radiat Oncol. 2017 Sep - Oct;7(5):295-301
pubmed: 28596092
Can J Surg. 2020 May 1;63(22):S2-S4
pubmed: 32343118
Int J Clin Oncol. 2014 Aug;19(4):570-8
pubmed: 24993673
Radiother Oncol. 2020 May;146:223-229
pubmed: 32342863
J Clin Oncol. 2019 May 20;37(15):1316-1325
pubmed: 30943123
Br J Radiol. 2017 Mar;90(1071):20160732
pubmed: 27885858
Lancet Oncol. 2017 Mar;18(3):347-356
pubmed: 28209296
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):752-759
pubmed: 31445956
PLoS One. 2020 Apr 9;15(4):e0231258
pubmed: 32271810
Lancet. 2020 Jul 4;396(10243):27-38
pubmed: 32479829
Clin Oncol (R Coll Radiol). 2020 Apr;32(4):250-258
pubmed: 31607611
Transl Lung Cancer Res. 2019 Sep;8(Suppl 2):S124-S134
pubmed: 31673516
Lancet Oncol. 2014 Jan;15(1):e42-50
pubmed: 24384493
J Thorac Oncol. 2012 May;7(5):825-32
pubmed: 22481232
Front Cell Dev Biol. 2020 Feb 13;8:41
pubmed: 32117972
J Thorac Oncol. 2015 Apr;10(4):577-85
pubmed: 25514807
Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1077-1084
pubmed: 30513377
J Thorac Oncol. 2020 Jun;15(6):1065-1072
pubmed: 32289516
JAMA. 2010 Mar 17;303(11):1070-6
pubmed: 20233825
Lancet Oncol. 2019 Apr;20(4):494-503
pubmed: 30770291
Ann Thorac Surg. 2020 Aug;110(2):692-696
pubmed: 32278755
Br J Surg. 2020 May 12;:
pubmed: 32395848
Chest. 2013 May;143(5 Suppl):e166S-e190S
pubmed: 23649437
J Thorac Oncol. 2019 Mar;14(3):482-493
pubmed: 30503889
Anticancer Res. 2014 Jun;34(6):3119-24
pubmed: 24922681
Lancet. 2019 May 18;393(10185):2051-2058
pubmed: 30982687
JAMA Oncol. 2019 May 1;5(5):681-688
pubmed: 30789648
J Thorac Cardiovasc Surg. 2019 Sep;158(3):895-907
pubmed: 31078312
Cell Death Differ. 2007 Jul;14(7):1237-43
pubmed: 17431418
Ann Thorac Cardiovasc Surg. 2019 Jun 20;25(3):129-141
pubmed: 30971647
Ann Thorac Surg. 2020 Mar;109(3):848-855
pubmed: 31689407